The 3-year relapse and mortality rates for thrombotic thrombocytopenic purpura (TTP) were 23.6% and 26.3%, predicated on platelet count. Platelet count was found to be a predictor of relapse in ...

An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial. X. Long Zheng, MD, PhD: Now we can talk about caplacizumab.

Therapeutic plasma exchange has been the essential treatment for acquired thrombotic thrombocytopenic purpura (TTP) since 1991. 1 Therefore, the diagnosis of TTP in a Jehovah’s Witness patient creates ...

Acquired thrombotic thrombocytopenic purpura (acquired TTP, or aTTP) is a rare blood disorder that results in blood clots in small blood vessels around your body. These clots can slow the flow of ...

For the past two years, the research lab of X. Long Zheng, M.D., Ph.D., Division Director, Laboratory Medicine, UAB Department of Pathology, has hosted an annual Thrombotic Thrombocytopenic Purpura ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Thrombocytopenia is an atypically low platelet count. Acquired thrombocytopenia is caused by conditions that develop throughout your life instead of genes inherited from birth. Acquired ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).